SynthesisClinical pharmacology and therapeutics2021
NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure.
Synthesis in Clinical pharmacology and therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of bioelectrical impedance technology on the prognosis of dialysis patients: a meta-analysis of randomized controlled trials.Renal failure · 2023Pooled it
- Trial
- Association between NT-proBNP changes and clinical outcomes in paediatric patients with heart failure: Insights from PANORAMA-HF and PARADIGM-HF.ESC heart failure · 2025Trial
- Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial.Circulation · 2024Trial
- In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial.European heart journal · 2024Trial
- Efficacy and safety of mavacamten in non-obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis of randomized trials.International journal of cardiology. Heart & vasculature · 2026Article
- Rivaroxaban plus antiplatelet therapy for coronary artery ectasia: 36-month outcomes and risk prediction from a retrospective cohort study.Frontiers in cardiovascular medicine · 2026Article
- The effect of a sustainable diet and time-restricted eating and probiotic in heart failure with reduced ejection fraction patients: study protocol for a randomized, double-blind, and placebo-controlled trial.Nutrition journal · 2025Article
- Association Between Levels of N-Terminal Pro-brain Natriuretic Peptide and Coronary Artery Lesion in Patients with Kawasaki Disease: A Systematic Review and Meta-analysis.Archives of rheumatology · 2025Article
- Initial outcomes of novel guideline-directed pharmacotherapy for systemic right heart failure in adults with congenital heart disease.Cardiovascular diagnosis and therapy · 2025Article
- NT-proBNP for Predicting All-Cause Death and Heart Transplant in Children and Adults with Heart Failure.Pediatric cardiology · 2025Observational
- Article
- Irisin Predicts Poor Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction and Low Levels of N-Terminal Pro-B-Type Natriuretic Peptide.Biomolecules · 2024Article
- Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat.Clinical pharmacokinetics · 2024Review
- Fasting Plasma Ketone Bodies Are Associated with NT-proBNP: A Potential Mechanism to Provide Fuel for the Failing Heart.Journal of clinical medicine · 2024Article
- Harmony in Chaos: Deciphering the Influence of Ischemic Cardiomyopathy and Non-Cardiac Comorbidities on Holter ECG Parameters in Chronic Heart Failure Patients: A Pilot Study.Medicina (Kaunas, Lithuania) · 2024Article
- Association between dietary inflammatory index and NT-proBNP levels in US adults: A cross-sectional analysis.PloS one · 2024Article
- Predictive Value of Smoking Index Combined with NT-proBNP for Patients with Pulmonary Hypertension Due to Chronic Lung Disease: A Retrospective Study.International journal of chronic obstructive pulmonary disease · 2024Article
- Clinical characteristics and biomarkers feature analysis using a proteomics platform in young patients with acute coronary syndrome.Frontiers in cardiovascular medicine · 2024Article
- Prognostic Value of Systemic Inflammation Response Index and N-Terminal Pro-B-Type Natriuretic Peptide in Patients with Myocardial Infarction with Nonobstructive Coronary Arteries- A Retrospective Study.Journal of inflammation research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a well-established biomarker in heart failure (HF) but controversially discussed as a potential surrogate marker in HF trials. We analyzed the NT-proBNP/mortality relationship in real-world data (RWD) of 108,330 HF patients from the IBM Watson Health Explorys database and compared it with the NT-proBNP / clinical event end-point relationship in 20 clinical HF studies. With a hierarchical statistical model, we quantified the functional relationship and interstudy variability. To independently qualify the model, we predicted outcome hazard ratios in five phase III HF studies solely based on NT-proBNP measured early in the respective study. In RWD and clinical studies, the relationship between NT-proBNP and clinical outcome is well described by an E
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.